Nolpitantium besilate

Drug Profile

Nolpitantium besilate

Alternative Names: SR 140333

Latest Information Update: 17 Jan 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator sanofi-aventis
  • Class Analgesics; Anti-inflammatories; Antiasthmatics; Antihypotensives; Antimigraines; Piperidines; Quinuclidines
  • Mechanism of Action Neurokinin 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Inflammation; Migraine; Nausea and vomiting; Pain; Ulcerative colitis

Most Recent Events

  • 01 Apr 2005 No development reported - Phase-II for Asthma in France (unspecified route)
  • 01 Apr 2005 No development reported - Phase-II for Inflammation in France (unspecified route)
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top